Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Cash Flow (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Net Cash Flow for 6 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 99.02% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$378.3 million through Dec 2025, down 191.95% year-over-year, with the annual reading at -$378.3 million for FY2025, 191.95% down from the prior year.
  • Net Cash Flow for Q4 2025 was $3.9 million at Janux Therapeutics, up from -$4.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $403.9 million in Q4 2024, with the low at -$356.9 million in Q1 2025.
  • Average Net Cash Flow over 5 years is $2.3 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Net Cash Flow tumbled 18917.56% in 2021, then soared 19571.26% in 2024.
  • Over 5 years, Net Cash Flow stood at -$3.0 million in 2021, then crashed by 345.54% to -$13.3 million in 2022, then surged by 115.41% to $2.1 million in 2023, then skyrocketed by 19571.26% to $403.9 million in 2024, then crashed by 99.02% to $3.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $3.9 million, -$4.1 million, and -$21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.